首页> 外文期刊>Open Journal of Veterinary Medicine >Evaluation of the Aurora Kinase Inhibitor, ZM447439, in Canine Malignant Lymphoid Cells in Vitro
【24h】

Evaluation of the Aurora Kinase Inhibitor, ZM447439, in Canine Malignant Lymphoid Cells in Vitro

机译:犬恶性淋巴样细胞中极光激酶抑制剂ZM447439的体外评价

获取原文
           

摘要

Aurora kinases play an important role in the cell cycle. These enzymes help establish mitotic spindles by directing centrosome duplication and separation and by regulating the spindle assembly checkpoint thereby helping control cytokinesis. An over-expression of aurora kinases has been reported in a variety of human tumors. In this study, we identified the expression of aurora-A and aurora-B kinases in canine malignant lymphoid cells. We also evaluated the effects of the aurora kinase inhibitor (ZM447439), and found that this inhibitor decreases cell viability, increases DNA content change, and leads to apoptosis in canine B- and T-cell lymphoid cell lines. The lymphotoxicity induced by ZM447439 in these canine lymphoid cell lines suggests that further in vivo evaluation of aurora kinase inhibitors as a potential treatment for canine malignant lymphoid tumors is warranted.
机译:极光激酶在细胞周期中起重要作用。这些酶通过指导中心体复制和分离并调节纺锤体装配检查点来帮助建立有丝分裂纺锤体,从而帮助控制胞质分裂。据报道,在多种人类肿瘤中极光激酶的过度表达。在这项研究中,我们确定了犬恶性淋巴样细胞中Aurora-A和Aurora-B激酶的表达。我们还评估了极光激酶抑制剂(ZM447439)的作用,发现该抑制剂降低了细胞活力,增加了DNA含量变化,并导致犬B细胞和T细胞淋巴样细胞系凋亡。 ZM447439在这些犬淋巴样细胞系中诱导的淋巴毒性表明,有必要进一步体内评估极光激酶抑制剂作为犬恶性淋巴瘤的潜在治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号